GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » Cyclically Adjusted PB Ratio

Pharma Equity Group AS (OCSE:PEG) Cyclically Adjusted PB Ratio : (As of May. 25, 2025)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Equity Group AS Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Pharma Equity Group AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS Cyclically Adjusted PB Ratio Chart

Pharma Equity Group AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.04 0.04 0.06 -

Pharma Equity Group AS Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.07 0.09 0.14 -

Competitive Comparison of Pharma Equity Group AS's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Pharma Equity Group AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's Cyclically Adjusted PB Ratio falls into.


;
;

Pharma Equity Group AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharma Equity Group AS's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Pharma Equity Group AS's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.04/118.9000*118.9000
=0.040

Current CPI (Dec. 2024) = 118.9000.

Pharma Equity Group AS Quarterly Data

Book Value per Share CPI Adj_Book
201203 50.617 98.300 61.224
201206 47.317 98.200 57.291
201209 44.434 98.700 53.528
201212 24.018 98.300 29.051
201303 21.164 99.300 25.341
201306 -21.039 99.100 -25.243
201309 -25.430 99.200 -30.480
201312 -69.597 99.000 -83.587
201403 -71.780 99.600 -85.689
201406 -32.363 99.700 -38.595
201409 -32.418 99.700 -38.661
201412 4.494 99.400 5.376
201503 4.474 100.200 5.309
201506 4.441 100.300 5.265
201509 4.403 100.200 5.225
201512 4.366 99.800 5.202
201603 4.349 100.200 5.161
201606 4.340 100.600 5.129
201612 4.338 100.300 5.142
201706 4.334 101.200 5.092
201712 3.595 101.300 4.220
201806 4.298 102.300 4.995
201812 3.257 102.100 3.793
201906 3.128 102.900 3.614
201912 2.111 102.900 2.439
202006 1.736 103.200 2.000
202012 1.077 103.400 1.238
202106 1.056 105.000 1.196
202112 1.141 106.600 1.273
202206 1.189 113.600 1.244
202209 0.000 116.400 0.000
202212 1.235 115.900 1.267
202303 0.060 117.300 0.061
202306 0.055 116.400 0.056
202309 0.050 117.400 0.051
202312 0.025 116.700 0.025
202403 0.031 118.400 0.031
202406 0.025 118.500 0.025
202409 0.019 118.900 0.019
202412 0.040 118.900 0.040

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharma Equity Group AS  (OCSE:PEG) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharma Equity Group AS Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group AS Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .